Prostate Cancer Topics

The On-Topic Netowork

Prostate Cancer > Efficacy


Efficacy
Efficacy
Efficacy
Efficacy
Efficacy

The following information is about Efficacy.

Efficacy Defined

The greatest ability of a drug of treatment to produce a result, regardless of dosage

This definition is in context to Prostate Cancer. See more contextual defintions for Efficacy.


Navigation: [ 1 2 3 4 5 Next ]

Neotropix initiates enrollment for neuroendocrine cancer study

Published October 10, 2008, 5:41 pm, Pharmaceutical Business Review

Neotropix, a clinical-stage development company focused on neuroendocrine cancer treatments, has started enrolling neuroendocrine cancer patients into an expanded clinical trial of its lead candidate, NTX-010, a tumor-selective naturally-occurring oncolytic virus.

Full Story


Cervical cancer shot gains acceptance

Published October 10, 2008, 4:10 pm, UPI

ATLANTA, Oct. 10 (UPI) -- One in four teenage girls received at least one dose of a relatively new vaccine against cervical cancer, U.S. health officials said.

Full Story


Lorus Therapeutics Announces Voluntary Delisting From the NYSE Alternext

Published October 10, 2008, 2:02 pm, CCNMatthews via Yahoo! Finance

TORONTO, ONTARIO-- - Lorus Therapeutics Inc. , a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that it has submitted written notice to the NYSE Alternext U.S., LLC of its intention to voluntarily delist its common shares from NYX.

Full Story


FDA Approves Rapaflo for the Treatment of Symptoms Due to an Enlarged Prostate Gland

Published October 10, 2008, 12:49 pm, U. S. Food and Drug Administration

The U.S. Food and Drug Administration today approved Rapaflo (silodosin) capsules for the treatment of symptoms due to benign prostatic hyperplasia (BPH), a condition also known as an enlarged prostate.

Full Story


NSAIDs Might Lower Breast Cancer Risk

Published October 10, 2008, 12:29 pm, MedicineNet.com

Title: NSAIDs Might Lower Breast Cancer Risk Category: Health News Created: 10/10/2008 2:00:00 AM Last Editorial Review: 10/10/2008

Full Story


A new alternative in treating short bowel syndrome

Published October 10, 2008, 6:45 am, EurekAlert!

( World Journal of Gastroenterology ) Short bowel syndrome is a clinical condition characterized by diarrhea, dehydration, electrolyte imbalance, malabsorption, and progressive malnutrition related to a wide resection of the small intestine. Chlorella is a species of green algae that grows in fresh water. In this study the authors evaluated the efficacy of chlorella extract which has rich amino ...

Full Story


Synageva BioPharma Appoints Leading Clinician and Industry Executive, Dr. Mark Goldberg, to its Board of Directors

Published October 10, 2008, 6:20 am, Centre Daily Times

Synageva BioPharma announced today the appointment of Mark Goldberg, M.D., Senior Vice President of Clinical Research at Genzyme Corp., and a leading medical oncologist and hematologist, to the Company's Board of Directors.

Full Story


ROTATEQ(R) Receives WHO Pre-qualification

Published October 10, 2008, 5:30 am, Business Wire via Yahoo! Finance

WHITEHOUSE STATION, N.J.----ROTATEQ® , the pentavalent rotavirus vaccine from Merck & Co., Inc., that helps prevent rotavirus gastroenteritis in infants and children, has been awarded pre-qualification status by the World Health Organization .

Full Story


Neotropix Announces Expansion Of On-Going Clinical Trial For Adult Neuroendocrine Cancers

Published October 10, 2008, 3:18 am, BioresearchOnline

Neotropix, Inc., a clinical-stage development company focused on neuroendocrine cancer treatments, announced recently that it has begun enrolling neuroendocrine cancer patients into an expanded clinical trial of its lead candidate, NTX-010 (SVV-001), a tumor-selective naturally-occurring oncolytic virus.

Full Story


Watson Receives US FDA Approval For RAPAFLO(TM) (silodosin) For The Treatment Of Benign Prostatic Hyperplasia (BPH)

Published October 10, 2008, 3:07 am, Medical News Today

Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved RAPAFLO(TM) (silodosin), the company's new alpha blocker for the treatment of the signs and symptoms of BPH.

Full Story


Navigation: [ 1 2 3 4 5 Next ]

Are you looking for additional Prostate Cancer > Efficacy news? Try our new "Efficacy News Focus" area.

Off-site Efficacy Links, User Submitted

The following links have been collected through user bookmark submission in the Efficacy category. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Wed Oct 8

Sat Oct 4

Thu Oct 2

Fri Sep 26

Tue Sep 16

If you would like to find additional social bookmark based links on the topic of we recommend the Open Tag Directory > Efficacy. If you would like to find related tags we recommend Tag Patterns > Efficacy

Off-site Efficacy Research Links

If you still need additional information on Efficacy then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Prostate Cancer

If you know the Prostate Cancer Term Name use the links below to quickly jump to your desired focus.



Bookmark Us

The On Topic Network

This website is part of The On Topic Network.

Thank You

Prostate-Cancer.On-Topic.net was developed by Odin Metatech, Inc and runs on the Odin Assemble platform.

Best Viewed With

License

Creative Commons License This work is licensed under Creative Commons.




Powered by Odin Assemble 2.5a